4-(2-Methylpropyloxy)phenylmethylamine (aka (4-Isobutoxyphenyl)methanamine, p-Isobutyloxybenzylamin) is a pharmaceutical intermediate typically used in the preparation of Pimavanserin, as a selective serotonin 2A receptor (5-HT2AR) inverse agonist, in treatment of psychotic symptoms in patients with Parkinson's disease.
On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis. 
(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. 
Novel and environmentally friendly synthesis of pimavanserin (5-HT2A receptor). 
 U.Hacksell, et al, Neurochem. Res., 2014, 39(10), pp 2008-2017.